Phaseline

Targets › TTK

TTK (Dual specificity protein kinase TTK): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Involved in mitotic spindle assembly checkpoint signaling, a process that delays anaphase until chromosomes are bioriented on the spindle, and in the repair of incorrect mitotic kinetochore-spindle microtubule attachments. Phosphorylates MAD1L1 to promote the mitotic spindle assembly checkpoint. (UniProt, P33981)

Open in Phaseline: the race on TTK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SillaJenBAL0891
Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
TTK, PLK1Phase 1Advanced Solid TumorDec 2026
Treadwell TherapeuticsCFI-402257
TTK inhibitor
TTKPhase 1Advanced Solid Tumor; Breast Cancer–

Conditions

Advanced Solid Tumor (2) Breast Cancer (2)

Modalities

mixed (1), small molecule (1)

Companies

SillaJen (1) Treadwell Therapeutics (1)

Related targets

PLK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.